

Daniele Raggi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9147108/publications.pdf>

Version: 2024-02-01

108
papers

2,857
citations

236912

25
h-index

206102

48
g-index

108
all docs

108
docs citations

108
times ranked

3087
citing authors

#	ARTICLE	IF	CITATIONS
1	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 10.e1-10.e6.	1.6	20
2	Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. <i>European Urology Oncology</i> , 2022, 5, 1-17.	5.4	50
3	Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group). <i>Immunotherapy</i> , 2022, 14, 107-114.	2.0	4
4	Von Hippelâ€“Lindau disease-associated renal cell carcinoma: a call to action. <i>Current Opinion in Urology</i> , 2022, 32, 31-39.	1.8	3
5	Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into Opportunities. <i>European Urology</i> , 2022, 81, 574-575.	1.9	7
6	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 155-164.	1.9	10
7	Impact of Novel Hormonal Therapy on Cognitive Function: Essential to Measure, Difficult to Present. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200092.	1.6	2
8	Adjuvant immunotherapy in patients with highâ€“risk muscleâ€“invasive urothelial carcinoma: The potential impact of informative censoring. <i>Cancer</i> , 2022, 128, 2892-2897.	4.1	6
9	Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 451-459.	5.4	11
10	Efficacy and toxicity of antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16536-e16536.	1.6	0
11	Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy. <i>Journal of Urology</i> , 2022, 208, 1046-1055.	0.4	1
12	Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. <i>European Urology Oncology</i> , 2021, 4, 802-810.	5.4	22
13	Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 237-245.e2.	1.9	5
14	Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2021, 7, 1092-1099.	3.1	4
15	Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?. <i>European Urology Oncology</i> , 2021, 4, 1006-1010.	5.4	11
16	Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. <i>European Urology Oncology</i> , 2021, 4, 1001-1005.	5.4	23
17	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 829-833.	5.4	20
18	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 48-53.	6.3	30

#	ARTICLE	IF	CITATIONS
19	Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer?. European Urology, 2021, 79, 713-716.	1.9	3
20	Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. European Urology Oncology, 2021, 4, 121-123.	5.4	5
21	[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e15-235.e21.	1.6	10
22	Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Clinical Medicine Insights: Oncology, 2021, 15, 117955492110216.	1.3	12
23	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. Journal of Urology, 2021, 205, 414-419.	0.4	3
24	Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study. International Journal of Cancer, 2021, 149, 186-190.	5.1	6
25	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). World Journal of Urology, 2021, 39, 3407-3414.	2.2	4
26	Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 159, 103241.	4.4	16
27	The Pros and Cons of "Machination of Medicine" in Genitourinary Oncology Practice. Bladder Cancer, 2021, , 1-5.	0.4	0
28	Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer. European Urology Open Science, 2021, 30, 34-36.	0.4	2
29	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. European Urology, 2021, 80, 149-159.	1.9	17
30	Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?. European Urology, 2021, 80, 319-322.	1.9	24
31	Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 734.e11-734.e17.	1.6	4
32	Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 631-641.	1.6	7
33	Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 37-37.	1.6	2
34	Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. BJU International, 2020, 125, 82-88.	2.5	20
35	Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. European Urology, 2020, 77, 269-276.	1.9	45
36	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. European Urology, 2020, 77, 439-446.	1.9	228

#	ARTICLE	IF	CITATIONS
37	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020, 77, 636-643.	1.9	75
38	Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-€positive penile squamous cell carcinoma. <i>BJU International</i> , 2020, 125, 867-875.	2.5	15
39	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 701-710.	1.9	128
40	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	1.9	41
41	Erdafitinib for the treatment of urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 835-846.	2.4	17
42	Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 531.e7-531.e15.	1.6	27
43	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , 2019, 11, 223.	3.7	18
44	An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. <i>European Urology</i> , 2019, 75, 201-203.	1.9	54
45	Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort. <i>European Urology Focus</i> , 2019, 5, 853-856.	3.1	8
46	Comparison of Fibroblast Growth-factor Receptor Gene Alterations at the DNA versus Messenger RNA Level in Advanced Urothelial Cancer: Insights for Clinical Research. <i>European Urology Focus</i> , 2019, 5, 689-692.	3.1	1
47	Role of Neoadjuvant and Adjuvant Chemotherapy in Penile Cancer. , 2019, , 845-850.		0
48	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2018, 53, 722-728.	2.4	5
49	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e961-e967.	1.9	14
50	Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. <i>European Journal of Cancer</i> , 2018, 96, 128-130.	2.8	9
51	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e403-e410.	1.9	11
52	Immunotherapy for metastatic urothelial carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 1-7.	1.8	6
53	First-€line therapy with dacomitinib, an orally available pan-€HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-€label, single-€arm, single-€centre, phase 2 study. <i>BJU International</i> , 2018, 121, 348-356.	2.5	70
54	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e1-8.e8.	1.6	8

#	ARTICLE	IF	CITATIONS
55	Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. <i>Journal of Urology</i> , 2018, 199, 741-747.	0.4	21
56	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3353-3360.	1.6	474
57	Role of Neoadjuvant and Adjuvant Chemotherapy in Penile Cancer. , 2018, , 1-6.		0
58	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 200, 1207-1214.	0.4	26
59	Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. <i>Future Oncology</i> , 2018, 14, 2683-2690.	2.4	1
60	Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 60-65.	1.3	4
61	Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e483-e487.	1.9	7
62	Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib. <i>Investigational New Drugs</i> , 2017, 35, 524-528.	2.6	9
63	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 509-512.e9.	1.9	1
64	Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. <i>Annals of Oncology</i> , 2017, 28, 1346-1351.	1.2	34
65	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	1.9	37
66	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 213-220.e5.	1.9	27
67	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 163-167.	1.9	3
68	A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 306-312.e3.	1.9	25
69	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 23-30.e2.	1.9	50
70	Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database. <i>Bone Marrow Transplantation</i> , 2017, 52, 1218-1220.	2.4	4
71	Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016, 2, 395-403.	0.4	13
72	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 52-64.	4.4	19

#	ARTICLE	IF	CITATIONS
73	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 494-498.	1.9	1
74	Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 249-254.	1.9	12
75	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 261-264.e4.	1.9	22
76	Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 518-523.	1.9	28
77	Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. <i>Journal of Endourology</i> , 2016, 30, 1112-1119.	2.1	20
78	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e81-e90.	1.9	4
79	Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. <i>Journal of Urology</i> , 2016, 196, 95-100.	0.4	70
80	Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 384-390.	2.4	7
81	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016, 34, 236-242.	2.6	21
82	Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 49-61.	1.2	108
83	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 624-633.	1.9	25
84	A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 323-330.	1.9	59
85	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 231-236.	1.9	38
86	The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 1-4.	1.9	6
87	Quality of Life and Pain Control following Laparoscopic Retroperitoneal Lymph Node Dissection in Early-stage Nonseminoma. <i>Tumori</i> , 2015, 101, 650-656.	1.1	6
88	Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases. <i>BJU International</i> , 2015, 116, 727-733.	2.5	23
89	Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 80-86.e1.	1.9	17
90	Clinical Outcome in Testicular Sex Cord Stromal Tumors: Testis Sparing vs Radical Orchiectomy and Management of Advanced Disease. <i>Urology</i> , 2015, 85, 402-406.	1.0	47

#	ARTICLE	IF	CITATIONS
91	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	1.6	12
92	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 385-391.e1.	1.9	4
93	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , 2015, 26, 657-668.	1.2	71
94	Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 152-161.	2.0	27
95	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 171-177.e1.	1.9	9
96	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015, 26, 167-172.	1.2	17
97	A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 87-93.e1.	1.9	27
98	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. <i>British Journal of Cancer</i> , 2014, 110, 26-33.	6.4	16
99	Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 203-209.e1.	1.9	15
100	Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 196-202.e1.	1.9	3
101	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β 2 (TGF β 2) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. <i>Investigational New Drugs</i> , 2014, 32, 555-560.	2.6	50
102	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 433-439.	1.9	24
103	Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 63-69.e1.	1.9	27
104	The Relationship between Characteristics of Inguinal Lymph Nodes and Pelvic Lymph Node Involvement in Penile Squamous Cell Carcinoma: A Single Institution Experience. <i>Journal of Urology</i> , 2014, 191, 977-982.	0.4	75
105	Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 376-376.	1.6	5
106	Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. <i>Annals of Oncology</i> , 2013, 24, 2887-2892.	1.2	14
107	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. <i>Journal of Urology</i> , 2013, 190, 1919-1924.	0.4	36
108	Pembrolizumab as Neoadjuvant Therapy Preceding Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Group, Phase 2 Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	12